Leading Stroke Companies in Vietnam | Key Players 2026

Leading Stroke Companies in Vietnam

The following is a data-backed list of the leading Vietnam Stroke companies, compiled through 6Wresearch's proprietary research and validated by in-house industry analysts. These companies represent the key players shaping competition in the Vietnam Stroke Industry, including DHG Pharmaceutical, Imexpharm Corporation, and other established names.

List of Stroke companies in Vietnam:

1. DHG Pharmaceutical

Leads local cardiovascular and neurological generic drug production, providing essential medicines for blood pressure and stroke risk management.

2. Imexpharm Corporation

Operates advanced EU-GMP standard facilities supplying high-quality prescription treatments utilized in chronic vascular and stroke care protocols.

3. Traphaco JSC

Focuses on modern pharmaceutical manufacturing and traditional integration to deliver circulatory support and neuroprotective wellness products.

4. Pymepharco

Supplies extensive portfolios of affordable cardiovascular formulations and antiplatelet medications supporting emergency stroke intervention units.

5. Domesco Medical Import-Export JSC

Manufactures specialized chronic disease treatments, focusing on hypertension control and therapeutic agents for cerebrovascular complications.

6. Bidiphar

Delivers critical hospital injectables and specialized therapeutic solutions applied across national neurology and emergency care departments.

7. Stellapharma

Offers rigorous quality-assured medications including advanced anti-thrombotic and cardiovascular drugs for comprehensive stroke therapy.

8. Vinmec Healthcare System

Operates advanced international-standard JCI-accredited hospitals featuring specialized neurology departments and acute stroke intervention centres.

9. Stroke International Services General Hospital

Specializes entirely in comprehensive cerebrovascular care, utilizing state-of-the-art neuroimaging and rapid acute stroke treatment technologies.

10. BV Pharma

Produces essential clinical pharmaceutical lines supporting long-term rehabilitation and secondary prevention therapies for stroke survivors.

Frequently Asked Questions About the Market Study (FAQs):